Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Opaviraline SCHEMBL29388810 | 1.00 | KMT2A (0.43) | KMT2AMAPK1MEN1MAOBMAPT | |
| Opaviraline SCHEMBL865250 | 1.00 | KMT2A (0.43) | KMT2AMAPK1MEN1MAOBMAPT | |
| SCHEMBL8001613 | 0.84 | KMT2A (0.43) | KMT2AMAPK1MEN1MAPTALDH1A1 | |
| SCHEMBL29778101 | 0.84 | GAA (0.35) | KMT2AMAOBMAPTALDH1A1GAA | |
| SCHEMBL4158564 | 0.83 | KMT2A (0.48) | KMT2AMAPK1MEN1MAPT | |
| SCHEMBL4916100 | 0.77 | MAPK1 (0.48) | KMT2AMAPK1MEN1MAPTALDH1A1 | |
| SCHEMBL4870381 | 0.77 | MAPK1 (0.48) | KMT2AMAPK1MEN1MAPTALDH1A1 | |
| SCHEMBL4870172 | 0.77 | MAPK1 (0.48) | KMT2AMAPK1MEN1MAPTALDH1A1 | |
| SCHEMBL8683704 | 0.74 | IDH1 (0.37) | KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL7801615 | 0.74 | IDH1 (0.37) | KMT2AMAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686113-B1 | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | claimed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | claimed |
| US-20020165233-A1 | Quinoxaline containing medicaments for post exposure prophylaxis of an HIV infection | MORI KAZUYASU (JP) | 2002-11-07 | — | — | US | claimed |
| WO-2000018384-A2 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDRO-2H-QUINOXALINE-1-CARBOXYLIC ACID ISOPROPYL ESTER AND AMPRENAVIR | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | claimed |
| WO-2000018383-A2 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2- ETHYL-7- FLUORO-3- OXO-3,4- DIHYDRO-2H- QUINOXALINE-1- CARBOXYLIC ACID ISOPROPYL ESTER | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | claimed |
| CN-119118932-A | Preparation method of C3-alkyl substituted quinoxalinone compound under heterogeneous photocatalysis | 南京工业大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-114907277-B | Quinoxalinone asymmetric hydrogenation process | 哈尔滨工业大学（深圳） | 2024-08-06 | — | — | CN | disclosed |
| CN-117402029-A | Synthesis method of chiral quinoxalinone | 西安交通大学 | 2024-01-16 | — | — | CN | disclosed |
| US-11419879-B2 | Methods for treating and preventing viral infections | ENTERIN, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| WO-2022133182-A1 | METHOD OF TREATING CORONAVIRUS INFECTION | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-9233943-B2 | Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | disclosed |
| WO-2000044729-A1 | CRYSTALLINE QUINOXALINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044729-A1 | CRYSTALLINE QUINOXALINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000018383-A3 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2- ETHYL-7- FLUORO-3- OXO-3,4- DIHYDRO-2H- QUINOXALINE-1- CARBOXYLIC ACID ISOPROPYL ESTER | GLAXO GROUP LTD (GB) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000018384-A3 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDRO-2H-QUINOXALINE-1-CARBOXYLIC ACID ISOPROPYL ESTER AND AMPRENAVIR | GLAXO GROUP LTD (GB) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000018384-A2 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDRO-2H-QUINOXALINE-1-CARBOXYLIC ACID ISOPROPYL ESTER AND AMPRENAVIR | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018384-A2 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDRO-2H-QUINOXALINE-1-CARBOXYLIC ACID ISOPROPYL ESTER AND AMPRENAVIR | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018383-A2 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2- ETHYL-7- FLUORO-3- OXO-3,4- DIHYDRO-2H- QUINOXALINE-1- CARBOXYLIC ACID ISOPROPYL ESTER | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018383-A2 | ANTIVIRAL COMBINATIONS COMPRISING (S)-2- ETHYL-7- FLUORO-3- OXO-3,4- DIHYDRO-2H- QUINOXALINE-1- CARBOXYLIC ACID ISOPROPYL ESTER | GLAXO GROUP LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | KMT2A 2991/4885MAPK1 4043/4885MEN1 1533/4885 |
| US-20020165233-A1 | Quinoxaline containing medicaments for post exposure prophylaxis of an HIV infection | CD68, G6PD, CD4 | KMT2A 1652/4885MAPK1 2237/4885MEN1 3858/4885 |
| US-11419879-B2 | Methods for treating and preventing viral infections | STING1, TSLP, MAVS | KMT2A 3381/4885MAPK1 4544/4885MEN1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.